The ablation technology market size is expected to advance at a CAGR of 9.0% during 2024–2030, to reach USD 9,672.9 million by 2030. This is attributed to the increasing demand for minimally invasive surgeries and the rising prevalence of cancer and cardiovascular diseases.
Moreover, studies suggest that ablation surgery may be more effective than drugs for arrhythmias. A recent randomized clinical trial, the results of which were published in The New England Journal of Medicine in November 2022, showed that using cryoballoon ablation initially has lower progression rates of A-fib than antiarrhythmic drugs.
Moreover, due to the benefits of minimally invasive procedures over conventional treatments, including shorter hospital stays, less pain, smaller and more-precise incisions, decreased risk of infection, speedier recovery, and less post-operative pain, the demand for ablation therapies has increased significantly.
Modern technology is used in minimally invasive procedures to identify and treat diseases, such as cancer. These techniques are used to remove lymph nodes and cancerous tumors without leaving scars. The collection of tissues for biopsies and precise staging tests can also be done minimally invasively. This helps surgeons in developing precise and appropriate cancer treatment regimens.
Radiofrequency ablators account for the largest share in the market, attributed to their wide usage in the treatment of atrial fibrillation and cancer. Moreover, the developments in radiofrequency ablators are expected to boost the market. For instance, in September 2022, Stryker Corporation announced that its OptaBlate bone tumor ablation system has received the 510(k) clearance from the U.S. Food and Drug Administration.
Moreover, in December 2022, NeuroOne Medical Technologies introduced a study of its OneRF ablation system, which uses implanted stereoelectroencephalography (sEEG) electrodes for tissue lesioning in the brain.
Laser ablation also holds a significant share in the market, due to the recent studies undertaken to unlock new applications for laser treatments. For instance, a study published in Dermatologic Surgery in December 2022 states that simple laser treatments may help prevent the development of non-melanoma cancer of the skin and basal cell carcinomas, which are collectively called keratinocyte carcinomas.
Hospitals are also introducing microwave ablation and thyroid radiofrequency ablation for the treatment of benign thyroid nodules. For instance, in January 2023, Tawam Hospital conducted the procedure on a 75-year-old patient with a benign thyroid nodule. The treatment was successful, and the patient was discharged within just one hour.
In the past, surgery was the only option for the thyroid nodule, but now, ablation is being used, as it is a non-invasive procedure that uses heat to destroy the tumor cell. The procedure shows more efficiency over surgery, and it is a time-saving option for patients and doctors as well.
Asia-Pacific is projected to witness the highest CAGR, of 9.5%, during the forecast period. This is attributed to the increasing awareness of minimally invasive techniques, rising investment in the enhancement of the healthcare system, and growing regional economics.
For instance, in December 2022, Kauvery Hospital in Chennai successfully performed minimally invasive radiofrequency ablation (RFA) on a 75-year-old woman suffering from abnormal heart rhythms. Untreated, this could have further led to tachycardia, bradycardia, or a more-severe arrhythmia.
Some of the key players in the market are Medtronic plc., Johnson & Johnson Services Inc., Abbott Laboratories, Boston Scientific Corporation, Olympus Corporation, Stryker Corporation, Smith & Nephew plc, Varian Medical Systems Inc., CONMED Corporation, and AngioDynamics Inc.